Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus complex
- Development stage
- Unknown
- Lead developer
- Beijing An Zhen Hospital
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus complex is a probiotic formulation typically composed of multiple live bacterial strains, most commonly including *Lactobacillus acidophilus*, *Lactobacillus bulgaricus*, and *Streptococcus thermophilus*. As a microbial therapy, it is designed to restore and maintain a healthy balance of gut microbiota. The preparation works by competitively inhibiting the growth of pathogenic bacteria, producing organic acids (such as lactic acid) that lower intestinal pH, and enhancing the mucosal barrier function. In clinical research, particularly at Beijing Anzhen Hospital, it has been evaluated for its potential to mitigate small intestinal mucosal injury induced by enteric-coated aspirin, a common complication of long-term antiplatelet therapy. By modulating the gut microbiome, the complex aims to reduce inflammation and promote the healing of aspirin-related intestinal lesions.
- Brand names
- Lactobacillus Triple Live Bacteria
- Other names
- lactobacillus complex capsules乳杆菌三联活菌
02
Targets
H (Histamine receptors)NPC1L1 (Niemann-pick C1-Like 1 transporter)AHR (Aryl hydrocarbon receptor)
Beyond the preview
Go deeper on lactobacillus complex.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus complex.